Patents by Inventor Jort Vellinga

Jort Vellinga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
    Patent number: 11896663
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: February 13, 2024
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
  • Potent and balanced bidirectional promoter
    Patent number: 11781155
    Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: October 10, 2023
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jort Vellinga
  • POTENT AND BALANCED BIDIRECTIONAL PROMOTER
    Publication number: 20230279425
    Abstract: The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Application
    Filed: September 7, 2022
    Publication date: September 7, 2023
    Inventors: Kerstin WUNDERLICH, Jort VELLINGA
  • Potent and balanced bidirectional promoter
    Patent number: 11473105
    Abstract: The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: October 18, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jort Vellinga
  • Adenovirus vectors and uses thereof
    Patent number: 11459583
    Abstract: Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 4, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Taco Gilles Uil, Soumitra Roy, Jort Vellinga, Selina Khan, Jerome H. Hv. Custers
  • POTENT AND SHORT PROMOTER FOR EXPRESSION OF HETEROLOGOUS GENES
    Publication number: 20210261984
    Abstract: The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 26, 2021
    Inventors: Kerstin WUNDERLICH, Taco Gilles UIL, Jort VELLINGA, Barbara Petronella SANDERS, Remko VAN DER VLUGT
  • Compositions and Vaccine Combinations Containing Synthetic Human Immunodeficiency Virus (HIV) Envelope Antigen, and Methods of Use Thereof
    Publication number: 20210220468
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Application
    Filed: March 3, 2021
    Publication date: July 22, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Danielle VAN MANEN, Jort VELLINGA, Frank WEGMANN, Benoit Christophe Stephan CALLENDRET, Anders KRARUP, Jörn STITZ
  • POTENT AND BALANCED BIDIRECTIONAL PROMOTER
    Publication number: 20210198694
    Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 1, 2021
    Inventors: Kirstin WUNDERLICH, Jort VELLINGA
  • Potent and short promoter for expression of heterologous genes
    Patent number: 11034978
    Abstract: The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 15, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Taco Gilles Uil, Jort Vellinga, Barbara Petronella Sanders, Remko Van Der Vlugt
  • Potent and balanced bidirectional promoter
    Patent number: 11001858
    Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: May 11, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jort Vellinga
  • Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens
    Patent number: 10973907
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
  • ADENOVIRUS VECTORS AND USES THEREOF
    Publication number: 20200347405
    Abstract: Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Application
    Filed: October 30, 2018
    Publication date: November 5, 2020
    Inventors: Taco Gilles UIL, Soumitra ROY, Jort VELLINGA, Selina KHAN, Jerome H.HV. Custers
  • HPV vaccines
    Patent number: 10744196
    Abstract: The present invention relates to novel vaccines against Human papillomavirus (HPV) infections, based on recombinant capsid-display adenovirus vectors. Described are capsid modified replication deficient adenovirus particles encoding and displaying multiple HPV L2 antigenic fragments, via a minor capsid protein IX, and their use for eliciting an immune response in order to provide protection against infections from multiple HPV types.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: August 18, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Marija Vujadinovic, Taco Gilles Uil, Koen Oosterhuis, Jort Vellinga, Jerôme Hubertina Henricus Victor Custers
  • Recombinant adenovirus expressing two transgenes with a bidirectional promoter
    Patent number: 10570417
    Abstract: The invention provides recombinant adenovirus (rAd) and rAd vectors comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such rAd and rAd vectors.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 25, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jerôme H. H. V. Custers, Jort Vellinga, Barbara Petronella Sanders
  • Adenovirus based malaria vaccine encoding and displaying a malaria antigen
    Patent number: 10517938
    Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CSshort) from a malaria-causing parasite, preferably P. falciparum, via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: December 31, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Jerôme H. H. V. Custers, Jort Vellinga, Marija Vujadinovic, Esmerelda Van Der Helm
  • Compositions and Vaccine Combinations Containing Synthetic Human Immunodeficiency Virus (HIV) Envelope Antigen, and Methods of Use Thereof
    Publication number: 20190321462
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 24, 2019
    Applicant: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria LANGEDIJK, Danielle VAN MANEN, Jort VELLINGA, Frank WEGMANN, Benoit Christophe Stephan CALLENDRET, Anders KRARUP, Jörn STITZ
  • POTENT AND BALANCED BIDIRECTIONAL PROMOTER
    Publication number: 20190264225
    Abstract: The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Application
    Filed: May 11, 2017
    Publication date: August 29, 2019
    Applicant: Janseen Vacines & Prevention B.V.
    Inventors: Kerstin WUNDERLICH, Jort VELLINGA
  • HPV VACCINES
    Publication number: 20190240312
    Abstract: The present invention relates to novel vaccines against Human papillomavirus (HPV) infections, based on recombinant capsid-display adenovirus vectors. Described are capsid modified replication deficient adenovirus particles encoding and displaying multiple HPV L2 antigenic fragments, via a minor capsid protein IX, and their use for eliciting an immune response in order to provide protection against infections from multiple HPV types.
    Type: Application
    Filed: July 11, 2017
    Publication date: August 8, 2019
    Inventors: Marija VUJADINOVIC, Taco Gilles UIL, Koen OOSTERHUIS, Jort VELLINGA, Jerôme Hubertina Henricus Victor CUSTERS
  • Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
    Patent number: 10369214
    Abstract: Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 6, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
  • POTENT AND BALANCED BIDIRECTIONAL PROMOTER
    Publication number: 20190225987
    Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 25, 2019
    Inventors: Kerstin WUNDERLICH, Jort VELLINGA